Breathe Well Live Well
|
BRIEF-Vectura's asthma drug meets main goal in mid-stage trial
Reuters Dec 11 (Reuters) – Vectura Group Plc. * Positive phase IIb/III results for VR475 in asthma. * Investigational drug/device combination VR475 met primary endpoint and has shown significant clinical benefit in a phase IIb/III trial in severe asthma patients. |
View full post on asthma – Google News
REM |
Array Biopharma Inc (NASDAQ:ARRY) attains midstage triumph for asthma …
FinancialsTrend Dallas, Texas 07/24/2013 (Financialstrend) – Array Biopharma Inc (NASDAQ:ARRY) has an additional benefit on deck for a prospective affiliation. The Boulder, CO-based medicine creator has touted upbeat Stage II facts for an experimental medicine in … Biotech News Bundle: BioCryst, NeoStem, Array Biopharma , Lexicon, GTx … Biotech Top Gainers,BioCryst Pharmaceuticals,Array Biopharma,NeoStem … Biotech Stocks Amid Structural And Capital Change: BioCryst Pharmaceuticals … |
View full post on asthma – Google News
|
Array asthma drug meets main goal in mid-stage study
Reuters (Reuters) – Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose as much as 19 percent to $6.64 — their highest … |
View full post on asthma – Google News
|
Array Seeks Asthma Drug Partner Following Mid-Stage Study Results
TheStreet.com BOULDER, Col. (TheStreet) — An experimental pill from Array BioPharma (ARRY) improved lung function in patients who suffer from asthma brought on by allergies, according to results from a small mid-stage study announced Tuesday. Array shares rose 15 … |
View full post on asthma – Google News
|
Array BioPharma scores midstage success for asthma drug
FierceBiotech Array BioPharma has another asset on deck for a potential partnership. The Boulder, CO-based drug developer has touted upbeat Phase II data for an experimental drug in patients with allergic asthma, and the company ($ARRY) plans to seek a partner to … Array asthma drug meets main goal in mid-stage study Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung … Array Seeks Asthma Drug Partner Following Mid-Stage Study Results |
View full post on asthma – Google News
|
Isis Spinoff Altair Therapeutics Shut Down, After Mid-Stage Asthma Study Fails
Xconomy … has shut down operations after the startup's only drug candidate failed in a mid-stage clinical trial against asthma, Xconomy has learned. … |
View full post on asthma – Google News